Unique ID issued by UMIN | UMIN000002844 |
---|---|
Receipt number | R000003457 |
Scientific Title | Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complex |
Date of disclosure of the study information | 2009/12/03 |
Last modified on | 2014/03/19 16:36:17 |
Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complex
Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complex
Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complex
Development of topical treatment with rapamycin for skin lesions of tuberous sclerosis complex
Japan |
tuberous sclerosis complex
Dermatology |
Others
NO
The purpose of this study is to develop an effective and safe treatment for skin lesions in tuberous sclerosis complex.
Safety,Efficacy
Pragmatic
Phase II,III
change in color and size of the skin lesions after 12 weeks topical treatment
change in shape
appearance of contact dermatitis
rapamycin levels in whole blood
Interventional
Parallel
Non-randomized
Open -no one is blinded
Placebo
3
Treatment
Medicine |
Application of 0.2% Rapamycin ointment (ointment base is 0.03% tacrolimus ointment) on skin lesion of one side of the face twice a day for 12 weeks.
Application of ointment base (control) on similar skin lesion of the other side of the face twice a day for 12 weeks.
Application of 0.2% Rapamycin ointment (ointment base is white petrolatum) on skin lesion of one side of the face twice a day for 12 weeks.
Application of ointment base (control) on similar skin lesion of the other side of the face twice a day for 12 weeks.
Application of 0.2% Rapamycin gel (base is carboxyvinyl polymer) on skin lesion of one side of the face twice a day for 12 weeks.
Application of gel base (control) on similar skin lesion of the other side of the face twice a day for 12 weeks.
Not applicable |
Not applicable |
Male and Female
1) Patients with a diagnosis of tuberous sclerosis complex made based on the clinical diagnostic criteria in guideline of Japanese Dermatological Association.
2) Patients who want to receive treatment for skin lesions of tuberous sclerosis complex.
3) Patients who cannot receive other effective treatment.
4) Patients who would not want to receive surgical treatment because of social circumstances or cosmetic reasons.
1) Patients with severe mental retardation who cannot carry out this treatment plan.
2) Patients with a past history of hypersensitivity to macrolide antibiotics.
3) Patients who were judged unsuitable for this study by the investigator.
21
1st name | |
Middle name | |
Last name | Mari Wataya-Kaneda |
Graduate School of Medicine, Osaka University
Department of Dermatology
2-2, Yamadaoka, Suita, Osaka 565-0871, JAPAN
06-6879-3031
mkaneda@derma.med.osaka-u.ac.jp
1st name | |
Middle name | |
Last name | Mari Wataya-Kaneda |
Graduate School of Medicine, Osaka University
Department of Dermatology
2-2, Yamadaoka, Suita, Osaka 565-0871, JAPAN
06-6879-3031
mkaneda@derma.med.osaka-u.ac.jp
Department of Dermatology
Graduate School of Medicine, Osaka University
Ministry of Health, Labour and Welfare
Japan
NO
大阪大学医学部附属病院
2009 | Year | 12 | Month | 03 | Day |
Published
Completed
2009 | Year | 09 | Month | 04 | Day |
2009 | Year | 09 | Month | 01 | Day |
2013 | Year | 07 | Month | 29 | Day |
2013 | Year | 07 | Month | 29 | Day |
2013 | Year | 07 | Month | 29 | Day |
2013 | Year | 07 | Month | 29 | Day |
2009 | Year | 12 | Month | 03 | Day |
2014 | Year | 03 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003457